Septic shock developed in 4 (14.8%) of the 27 neutropenic patients with A. baumannii-associated bacteremia, and 2 (7.4%) of the 27 died (Table) . However, we did not fi nd a statistically signifi cant association between death among patients with bacteremia caused by MDR A. baumanni (1 death) compared with death among those with bacteremia caused by A. baumannii strains susceptible to the carbapenems, ciprofl oxacin, and amikacin (1 death) (Table) . This fi nding is similar to that described by Sunenshine et al. (1) in the general ICU population and in neutropenic cancer patients with bacteremia; however, multivariate analysis was not conducted to control for severity of illness and coexisting illness. In conclusion, neutropenic cancer patients with bacteremia due to MDR A. baumannii infection do not appear to be at increased risk for death compared with patients with bacteremia due to antimicrobial drug-susceptible A. baumannii. (1) . N. meningitidis serogroup X was fi rst described in the 1960s and has been found to cause a few cases of invasive disease across North America, Europe, and Africa (2). In Africa, small serogroup X outbreaks have been described in Ghana (9 cases over a 2-year period) and in Niger (134 cases between 1995 and 2000) (3, 4) . In 2006, however, 51% of 1,139 confi rmed cases of meningococcal meningitis in Niger were found to be caused by serogroup X (5 Over the course of the outbreak, cerebrospinal fl uid samples were obtained from 18 patients. Due to low population density, poor access to seminomadic populations, and the limited nature of the outbreak (relatively small numbers dispersed over a wide geographic region), obtaining specimens from untreated patients in West Pokot proved diffi cult. Three of the 5 fi rst samples were found to show gram-negative diplococci on staining, the next 2 were negative on Pastorex rapid latex agglutination test (Bio-Rad Laboratories, Hercules, CA, USA) (during the outbreak investigation), and a subsequent 13 were sent to the African Medical and Research Foundation (AMREF) laboratory in Nairobi, Kenya, for culture and susceptibility testing. From these 13 specimens, 2 yielded a pure growth of N. meningitidis serogroup X, while no growth was observed for the remaining 11 specimens. These 2 cultures were subsequently confi rmed as serogroup X by the World Health Organization Collaborating Centre for Meningococci in Oslo, Norway. Multilocus sequence typing and sequencing of the porA and fetA genes as described (http:// pubmlst.org/neisseria/), showed that the infecting strain belonged to a new sequence type, ST-5403, and that it was subtype P1.19,26 and FetA type F3-27. This sequence type is unrelated to other serogroup X isolates from Africa, including those from the latest serogroup X outbreak in Niger, but it resembles a sequence type isolated in the United States in the 1970s. In addition to the testing at AMREF and in the Oslo laboratory, the 13 samples were also analyzed by PCR at the US Naval Medical Research Unit No. 3 in Cairo, Egypt. Overall, 5 of these 13 specimens were positive for serogroup X (including the 2 samples found to be serogroup X at AMREF and confi rmed by PCR in Oslo) and 1 each was positive for serogroups C, W135, and Y. At the same time as this outbreak in Western Kenya, a meningococcal meningitis outbreak was being monitored across the border in the Karamoja region of northeastern Uganda. Seminomadic populations move freely across the 2 countries, and we can assume that there was 1 meningitis outbreak that started in eastern Uganda and spread to Western Kenya. Although initial laboratory testing in Uganda suggested the presence of serogroup A, among 23 specimens subsequently sent to the Oslo laboratory, 11 were identifi ed as serogroup X by PCR and 3 were serogroup W135 (6) . Therefore, the outbreaks in both Kenya and Uganda involved multiple N. meningitidis serogroups. In West Pokot, Kenya, the Ministry of Health and Médecins sans Frontières conducted a vaccination campaign using the trivalent polysaccharide vaccine against serogroups A, C, and W135.
Before 2006, previous disease outbreaks caused by serogroup X had not reached the magnitude of those caused by serogroups A, C, or W135; they tended to evolve independently of the occurrence of both serogroups A and C and to be self-limited (3, 4) . Although most of Kenya is not included in the African meningitis belt, large epidemics of meningococcal disease have been reported previously (7) . In conclusion, we would like to highlight the presence of N. meningitidis serogroup X in East Africa, its potential involvement in disease outbreaks, and the diffi culties it may cause for laboratory confi rmation and, consequently, for making an appropriate epidemic response. 
